117 related articles for article (PubMed ID: 22088654)
1. Re: therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma.
Atala A
J Urol; 2011 Feb; 185(2):752. PubMed ID: 22088654
[No Abstract] [Full Text] [Related]
2. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma.
Gao P; Ding Q; Wu Z; Jiang H; Fang Z
Cancer Lett; 2010 Apr; 290(2):157-66. PubMed ID: 19786319
[TBL] [Abstract][Full Text] [Related]
3. Application of gene transfer in cancer immunotherapy. From experimental data to clinical protocols.
Favrot MC; Puisieux I
Adv Exp Med Biol; 1998; 451():539-41. PubMed ID: 10026924
[No Abstract] [Full Text] [Related]
4. Immune gene therapy for kidney cancer: the search for a magic trigger.
Kim HL; Belldegrun AS; Figlin RA
Mol Ther; 2003 Feb; 7(2):153-4. PubMed ID: 12597902
[No Abstract] [Full Text] [Related]
5. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Kudo-Saito C; Wansley EK; Gruys ME; Wiltrout R; Schlom J; Hodge JW
Clin Cancer Res; 2007 Mar; 13(6):1936-46. PubMed ID: 17363550
[TBL] [Abstract][Full Text] [Related]
6. Gene-modified immunotherapy for renal cell carcinoma.
Kawai K; Tani K; Asano S; Akaza H
Contrib Nephrol; 1999; 128():75-81. PubMed ID: 10597379
[No Abstract] [Full Text] [Related]
7. [Not Available].
Rupp NJ; Mischo A; Moch H
Ther Umsch; 2017 Sep; 74(4):171-179. PubMed ID: 28950771
[No Abstract] [Full Text] [Related]
8. Tissue inhibitor of metalloproteinase expression. A target for gene therapy in renal cell carcinoma.
McElligott AM; Baker AH; McGlynn H
Adv Exp Med Biol; 1998; 451():73-7. PubMed ID: 10026853
[No Abstract] [Full Text] [Related]
9. IL-2 therapy proves durable in renal cell melanoma patients.
Oncology (Williston Park); 1991 Sep; 5(9):71. PubMed ID: 1835879
[No Abstract] [Full Text] [Related]
10. Adjuvant treatment with IL-2 or interferon-alpha in renal cell carcinoma: a French multicentric study.
Soret JY; Escudier B
Cancer Biother Radiopharm; 1996 Oct; 11(5):301-2. PubMed ID: 10851508
[No Abstract] [Full Text] [Related]
11. [Tumor-specific gene therapy strategy for renal cell carcinomas].
Ogura M; Shibata T; Harada H; Hiraoka M
Nihon Rinsho; 2006 Feb; 64 Suppl 2():672-5. PubMed ID: 16523975
[No Abstract] [Full Text] [Related]
12. A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma.
Hum Gene Ther; 1992 Dec; 3(6):691-703. PubMed ID: 1482709
[No Abstract] [Full Text] [Related]
13. Anti-IL-2 anti-IL-4 monoclonal antibodies do not synergize in the suppression of mouse renal cancer.
Takeuchi T
J Chemother; 2010 Jun; 22(3):215-6. PubMed ID: 20566430
[No Abstract] [Full Text] [Related]
14. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
Parkinson DR; Sznol M
Semin Oncol; 1995 Feb; 22(1):61-6. PubMed ID: 7855620
[No Abstract] [Full Text] [Related]
15. Progress in therapy of renal cell cancer.
Rugarli C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S19-20. PubMed ID: 2697574
[No Abstract] [Full Text] [Related]
16. Treatment of metastatic melanoma and renal cell carcinoma with interleukin-2.
Manson LA
JAMA; 1994 Nov; 272(17):1327. PubMed ID: 7933390
[No Abstract] [Full Text] [Related]
17. Renal cell carcinoma and interleukin-2: what are the endpoints?
Figlin RA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S68-9. PubMed ID: 9457397
[No Abstract] [Full Text] [Related]
18. Renal-cell carcinoma.
Atkins MB; Dutcher JP
N Engl J Med; 1997 Mar; 336(11):809; author reply 810-1. PubMed ID: 9064517
[No Abstract] [Full Text] [Related]
19. Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK.
Kim SW; Kim SJ; Park SH; Yang HG; Kang MC; Choi YW; Kim SM; Jeun SS; Sung YC
Clin Cancer Res; 2013 Jan; 19(2):415-27. PubMed ID: 23204131
[TBL] [Abstract][Full Text] [Related]
20. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.
Mendiratta SK; Quezada A; Matar M; Thull NM; Bishop JS; Nordstrom JL; Pericle F
Hum Gene Ther; 2000 Sep; 11(13):1851-62. PubMed ID: 10986558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
